PTPI (Petros Pharmaceuticals) Tariff Resilience Score: 6/10 (As of Jun. 29, 2026)


What is Petros Pharmaceuticals Tariff Resilience Score?

Petros Pharmaceuticals PTPI -2.36% Tariff Resilience Score is 6 as of Jun. 29, 2026. Among 1,028 Drug Manufacturers companies, Petros Pharmaceuticals ranks better than 91.15% on this metric.

Petros Pharmaceuticals has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Petros Pharmaceuticals has Petros Pharmaceuticals has moderate exposure due to its reliance on imported raw materials. However, its domestic market focus and potential for alternative suppliers provide some resilience against tariffs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Petros Pharmaceuticals might have Average Resilient.

Petros Pharmaceuticals  (OTCPK:PTPI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Petros Pharmaceuticals Tariff Resilience Score Related Terms

PTPI vs STEK, KOAN, GCAN: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Petros Pharmaceuticals Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
Petros Pharmaceuticals (PTPI) has a Tariff Resilience Score of 6 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Petros Pharmaceuticals ranks #91 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is Petros Pharmaceuticals' Tariff Resilience Score too high?
Petros Pharmaceuticals' current Tariff Resilience Score is 6. Based on the distribution chart, Petros Pharmaceuticals ranks #91 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Petros Pharmaceuticals' Tariff Resilience Score compare to STEK and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #91 out of 1028 companies for Tariff Resilience Score. This places Petros Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Petros Pharmaceuticals's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Tariff Resilience Score is 6 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petros Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.